Skip to main content

Table 2 Prevalence of pfcrt 76 polymorphisms in pre-treatment samples in different categories of CQ treatment outcomes

From: Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications

 

Treatment outcome

Type of pfcrt-76 polymorphism

ACPR (%)

ETF (%)

LCF (%)

LPF (%)

All (%)

Pfcrt-T76 mutant-type

42 (95.5)

23 (100)

15 (100)

29 (96.7)

109 (97.3)

Pfcrt-K76 wild-type

2 (4.5)

0

0

0

2 (1.8)

Pfcrt-T76/K76 mixed-type

0

0

0

1 (3.3)

1 (0.9)

Total (%)

44 (100)

23 (100)

15 (100)

30 (100)

112 (100)